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Summary
Introduction:  Clostridium  difﬁcile  is  a  serious  reemerging  pathogen  in  Europe  and
North  America.  C.  difﬁcile  infection  (CDI)  has  been  of  concern  over  the  last  decade
in  view  of  its  signiﬁcant  morbidity  and  mortality,  as  well  as  the  high  health  care  costs
involved  with  each  case.  Although  multiple  risk  factors  are  known  to  be  associated
with  CDI,  a  number  of  patients  develop  severe  infection  even  in  the  absence  of  known
risk  factors.  CDI  is  diagnosed  by  the  detection  of  the  toxin  A/B  in  stools  by  enzyme
immunoassay  (EIA)  or  by  polymerase  chain  reaction  (PCR).  There  is  conﬂicting  liter-
ature  regarding  whether  any  particular  group  of  antibiotics  is  associated  with  higher
risk  for  CDI.  There  is  also  a  tendency  to  perform  repeated  stool  tests  for  toxin  A/B
if  the  ﬁrst  test  is  negative.  We  evaluated  100  consecutive  hospitalized  patients  who
tested  positive  for  C.  difﬁcile  over  a  one-year  period.
Methods:  We  performed  a  retrospective  analysis  of  100  consecutive  patients  with
CDI  admitted  to  our  hospital  between  July  2008  and  June  2009.  Patient  records  were
reviewed  for  risk  factors,  treatment,  and  clinical  outcomes.  We  also  evaluated  the
number  of  stool  tests  performed  for  the  detection  of  C.  difﬁcile  and  fecal  leukocyte
testing  in  each  patient.
Results:  The  majority  of  the  patients  were  more  than  60  years  of  age  (87%).  Forty-
four  percent  of  patients  presented  from  a  nursing  facility.  More  than  50%  were  on
Proton  Pump  Inhibitors  (PPIs)  at  the  time  of  admission.  Co-morbidities  in  our  patients
included  malignancy  in  28%,  diabetes  mellitus  in  25%,  and  chronic  renal  disease
in  23%.  Most  of  the  patients  had  multiple  co-morbidities.  Patients  who  had  taken
antibiotics  in  the  previous  six  months  constituted  74%  of  the  total  study  population.
A  beta-lactam  alone  or  in  combination  with  other  antibiotics  was  prescribed  in  48%,
quinolones  in  13%  and  clindamycin  in  4%  of  patients.  Stool  samples  were  tested  only
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Introduction
Clostridium  difﬁcile  is  a  spore-forming  anaerobic
bacillus found  in  the  normal  colonic  ﬂora  of  5%  of
healthy  adults  [1],  and  these  carriers  may  play  a sig-
niﬁcant role  in  the  transmission  of  this  infection  in
hospitals [2].  C.  difﬁcile  infection  (CDI)  is  the  most
common  cause  of  nosocomial  infectious  diarrhea  in
developed countries  and  its  incidence  has  been  ris-
ing steadily.  CDI  is  widespread  in  Massachusetts’s
hospitals [3].  CDI  is  responsible  for  increased  mor-
bidity and  a  substantial  economic  burden.  The
economic  impact  of  this  disease  is  expected  to
increase  in  the  coming  years.  The  widespread  use
of antibiotics  has  contributed  to  the  spread  of  this
disease  to  some  extent,  as  antimicrobial  therapy
plays a  major  role  in  the  pathogenesis  of  CDI,
presumably through  the  disruption  of  indigenous
intestinal microﬂora,  thereby  allowing  C.  difﬁcile
to grow  and  produce  toxins.  There  is  conﬂicting  lit-
erature regarding  whether  any  one  particular  group
of antibiotics  is  associated  with  a  higher  risk  for  CDI.
While clindamycin  has  been  known  for  many  years
as a  risk  factor,  some  studies  found  ﬂuoroquinolones
as a  high  risk  [4—6]  while  other  authors  have  impli-
cated  cephalosporins  as  high-risk  antibiotics  [7,8].
There  have  been  studies  published  to  assess
the need  for  repeated  stool  testing  in  the  diag-
nosis of  CDI  [9,10]. The  updated  Clinical  Practice
Guidelines for  CDI  in  adults  by  the  Society  for
Healthcare Epidemiology  for  America  (SHEA)  and
the Infectious  Diseases  Society  of  America  (IDSA)
have  advised  against  repeat  testing  during  the  same
episode of  diarrhea  [11].  Additionally,  there  has
been conﬂicting  evidence  regarding  the  need  for
fecal leukocyte  testing  (FLT)  as  a  screening  test  for
CDI. While  some  authors  have  concluded  that  FLT  is
a poor  predictor  of  CDI  [9,12], others  have  proposed
that FLT  might  be  useful  [1,13].
We present  our  experience  regarding  CDI  in
patients evaluated  over  a  one-year  period  in  a
280-bed  community  teaching  hospital,  with  the
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ice  or  more  in  43%.  Metronidazole  was  the  initial  therapy
are  unit  stay  was  required  in  33%  of  patients.  Seventeen
pitalization.
 are  especially  vulnerable  to  CDI  when  exposed  to  antibi-
nd  morbidity  is  observed  in  this  age  group.  PPI  use  was
onidazole  was  used  as  the  ﬁrst  line  agent  in  the  majority
ned  a  tendency  to  test  for  the  C.  difﬁcile  toxin  in  more
these  practices  need  to  be  modiﬁed  based  on  the  current
ziz  University  for  Health  Sciences.  Published  by  Elsevier
lderly  forming  a signiﬁcant  percentage  of  in-
ospital admissions.  We  performed  a retrospective
nalysis of  100  patients  admitted  to  our  hospital
ith CDI  between  July  2008  and  June  2009.
aterials and methods
 retrospective  analysis  of  100  consecutive  patients
iagnosed  with  CDI  who  were  admitted  to  the
ospital between  July  2008  and  June  2009  was  per-
ormed by  reviewing  electronic  medical  records.
DI diagnosis  was  based  on  a positive  EIA  for  toxin
/B in  stool.  PCR  is  not  available  at  our  hospi-
al. Approval  for  the  study  was  obtained  from  the
ospital’s  Institutional  Review  Board.  The  inclu-
ion criteria  were:  patients  more  than  18  years
f age,  with  a history  of  diarrhea  as  documented
n the  chart,  and  documented  CDI  by  EIA  testing
or toxin  A/B.  The  exclusion  criteria  were  patients
ith diarrhea  but  negative  EIA  testing.  The  patient
ata extracted  from  the  medical  records  included
ge, sex,  presentation  from  home  versus  nursing
acility  (including  nursing  homes,  short-term  and
ong-term  rehabilitation  facilities),  co-morbidities
 diabetes  mellitus,  malignancy,  kidney  disease,
ypertension, coronary  artery  disease,  antibiotic
se in  the  previous  6  months  along  with  the  nature
f the  antibiotic  (based  on  a review  of  previous
ospital records,  nursing  facility  records  and  out-
atient EMRs  if  available),  the  use  of  PPIs,  hospital
ourse and  outcomes.  We  also  evaluated  the  num-
er of  stool  samples  tested  by  EIA  for  toxin  A/B  and
esting  for  fecal  leukocytes.
esultsorty-eight  patients  were  female  and  52  were  male.
he median  age  was  80  years  (30—96  years),  87%
f patients  were  above  60  years  of  age,  of  which
8% were  above  the  age  of  80  years  (Table  1).
The  evaluation  of  CDI  in  a  community  hospital  
Table  1  Demographics.
Total  number  100
Age  distribution
18—40  years  4
41—60  years  6
61—80  years  39
>80  years  48
Presenting  from
Home  56
Hospital  or  nursing  facility 44
Co-morbidities
Malignancy  28
Diabetes  25
Chronic  renal  disease  23
Medications  at  admission
T
i
h
o
f
s
n
t
d
ﬁ
2
p
o
i
m
c
t
r
p
p
b
r
d
a
C
c
o
a
j
4
c
i
m
d
O
o
s
cPPIs  52
Laxatives  27
here  were  44  patients  who  presented  from  a nurs-
ng facility.  Eighty-ﬁve  percent  of  patients  had  a
istory of  admission  to  a  hospital  in  the  previ-
us 6  months.  Symptoms  at  presentation  included
ever  (>38 ◦C)  34%,  abdominal  pain  31%,  leukocyto-
is (>11  cells  ×  109/L)  67%  and  bandemia  30%.  The
umber  of  episodes  of  loose  stools  and  the  dura-
ion of  disease  prior  to  presentation  was  not  well
ocumented  in  the  majority  of  patients.  Twenty-
ve percent  of  patients  had  diabetes  mellitus,
3% had  chronic  renal  disease  and  malignancy  was
resent  in  28%  of  patients.  Seventy-four  percent
t
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f  patients  had  deﬁnitely  received  an  antibiotic
n the  previous  6  months  (Fig.  1). Beta-lactams,
ore precisely,  cephalosporins  (ﬁrst  generation
efalexin and  cefazolin  for  skin  infections,  and
hird-generation  ceftriaxone  and  cefpodoxime  for
espiratory infections),  were  the  most  commonly
rescribed antibiotics.  Forty-eight  percent  of
atients  had  received  beta-lactam  alone  or  in  com-
ination  with  vancomycin  or  macrolide,  13%  had
eceived a  quinolone  and  4%  had  received  clin-
amycin. Seven  patients  had  not  received  any
ntibiotic in  the  6  months  prior  to  presentation  with
DI. Documentation  regarding  prior  antibiotic  use
ould not  be  deﬁned  in  19  patients.  In  terms  of
ther gastrointestinal  medications  at  the  time  of
dmission,  52%  were  on  PPIs.
Stool samples  were  tested  for  toxin  A/B  by  EIA
ust once  in  53%  of  patients  and  twice  or  more  in
3% of  patients.  Stools  were  tested  for  fecal  leuko-
ytes  in  75  patients.  There  were  no  fecal  WBC  noted
n the  majority  of  patients  (42.6%)  and  only  32%  had
ore than  25  WBCs  per  high  power  ﬁeld.  Metroni-
azole was  the  initial  therapy  in  86%  of  patients.
ral vancomycin  was  used  in  43  patients.  In  terms
f clinical  outcomes,  the  median  length  of  hospital
tay was  6.5  days  (2—45  days).  Twenty-three  per-
ent of  patients  required  hospitalization  for  more
han 10  days  and  33%  of  patients  required  ICU
dmission. There  was  a  high  mortality  (17%)  rate
n our  study.
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Discussion
Our  data  are  consistent  with  the  previously  pub-
lished literature  that  the  elderly  population  is  at
high risk  for  CDI.  Eighty-seven  patients  in  our  study
were more  than  60  years  of  age  and  10  patients
were older  than  90  years.  This  is  in  part  a  reﬂection
of the  population  being  served  by  our  community
hospital. Many  of  our  elderly  patients  presented
from a  nursing  facility.  While  it  was  surprising
that 54%  of  patients  in  our  study  presented  from
home, the  majority  of  these  patients  had  a his-
tory of  hospitalization  in  the  previous  6  months.
Co-morbidities commonly  noted  were  malignancy,
diabetes mellitus  and  chronic  renal  disease.  This  is
again consistent  with  the  fact  that  when  the  host
immunity  is  compromised,  patients  are  at  a higher
risk of  acquiring  CDI.  The  majority  of  patients  in
our study  had  received  antibiotics  in  the  past  six
months.  The  most  commonly  implicated  class  of
antibiotics  was  cephalosporin  either  alone  or  in
combination  (48%).  Fluoroquinolone  was  used  in
only 13%  of  patients.  It is  the  opinion  of  the  authors
that this  is  reﬂection  of  the  pattern  of  antibiotic  use
rather than  a  direct  etiologic  relationship  between
cephalosporins  to  CDI,  especially  in  light  of  multi-
ple studies  that  have  implicated  ﬂouroquinolones
as well  as  cephalosporins  as  risk  factors  for  CDI
[4—8].  Stevens  and  colleagues  have  proposed  that
the cumulative  exposure  to  antibiotics  over  time
may play  a  more  signiﬁcant  role  in  the  risk  for
CDI rather  than  a  single  short  course  of  a given
antibiotic [14].  Interestingly,  seven  patients  had
no history  of  antibiotic  use  in  the  preceding  six
months. Four  of  these  patients  had  a  history  of
hospitalization  in  the  previous  6 months.  Regard-
less of  the  limitations  of  this  study  in  terms  of
the inability  to  capture  all  outpatient  antibiotic
use, this  ﬁnding  could  imply  that  multiple  unde-
ﬁned factors  may  contribute  to  the  development
of CDI  in  many  patients.  Manges  and  colleagues
concluded that  changes  in  the  intestinal  ﬂora  in
hospitalized  patients  are  not  driven  exclusively  by
antibiotic  use  and  a  number  of  cofactors  includ-
ing nonsteroidal  anti-inﬂammatory  drug  use  may
play an  important  role  in  the  development  of  CDI
[15].  David  Eyre  and  colleagues  performed  whole-
genome  sequencing  on  samples  from  patients  with
CDI and  found  that  the  majority  of  infections  arise
from genetically  diverse  sources  [16].  In  any  case,
the increasing  incidence  of  CDI  is  a  call  to  improve
antimicrobial stewardship  programs  in  health-care
settings  [17,18].Fifty-two  patients  were  noted  to  be  on  a PPI  at
the time  of  CDI  diagnosis.  There  has  been  some
conﬂicting literature  regarding  the  role  of  PPIs  in
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elation  to  CDI.  Some  studies  have  documented  an
ncreased  incidence  of  CDI  with  the  use  of  PPIs
19—21], while  others  have  not  conﬁrmed  this  [22].
he diagnosis  of  CDI  using  a clinical  deﬁnition  of
iarrhea and  the  detection  of  toxin  A/B  in  the
tool by  EIA  has  a sensitivity  that  varies  between
3% and  94%,  and  a  speciﬁcity  ranging  from  75%  to
00%. These  tests  have  been  adopted  by  more  than
0% of  laboratories  in  the  United  States  because  of
heir ease  of  use.  Processing  a single  specimen  from
 patient  at  the  onset  of  a  symptomatic  episode
sually has  been  considered  sufﬁcient.  Because  of
he low  increase  in  yield  and  the  possibility  of
alse-positive  results,  routine  testing  of  multiple
tool specimens  is  not  recommended  [11,23]. In
ur study,  stools  were  tested  for  toxin  A/B  in  more
han one  sample  in  43%  of  patients.  This  practice  of
epeat testing  needs  to  be  discontinued  based  on
he current  guidelines  [10]. Newer  more  sensitive
ests  are  now  available  at  our  facility.  Fecal  leuko-
ytes were  evaluated  in  75  patients,  and  this  test
ound no  WBCs  in  the  majority  of  patients.  There
ere many  WBCs  noted  in  24  patients  (32%).  This
uestions the  practice  of  testing  for  fecal  leuko-
ytes  in  stool  specimens  in  patients  with  suspected
DI.
Thirty-three of  our  patients  required  admission
o the  intensive  care  unit  (ICU).  There  were  23
atients  who  required  more  than  10  days  of  hospi-
alization.  There  were  no  cases  of  toxic  megacolon
r surgical  intervention.  Unfortunately,  there  was
igh mortality  rate  (17%)  in  our  study.  All  these
ndings taken  together  could  be  a reﬂection  of
he elderly  population  with  multiple  co-morbidities
escribed in  our  study.
Three  factors  have  been  used  to  deﬁne  the
everity of  illness  in  patients  with  CDI  —  age,  leuko-
ytosis and  creatinine  [11].  Two  of  these  three
actors were  observed  in  the  majority  of  our  study
atients  (87%  of  patients  were  above  60  years  of
ge and  67%  of patients  had  leukocytosis).  Met-
onidazole was  the  initial  therapy  in  86%  of  the
atients.  With  33  patients  requiring  an  ICU  stay  and
3 patients  requiring  more  than  10  days  of  hospital-
zation,  the  authors  conclude  that  oral  vancomycin
ould have  been  a better  ﬁrst  line  therapy  in  many
f these  patients  and  would  be  consistent  with
he guidelines  that  recommend  oral  vancomycin  as
he initial  choice  in  patients  with  severe  disease
11,24].
The main  limitations  of  our  study  are  sec-
ndary to  its  retrospective  observational  natureegarding the  frequency  of  loose  stools,  chronic
enal disease  (creatinine  values),  glycemic  con-
rol (hemoglobin  A1C),  details  of  cancer  and
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[he  evaluation  of  CDI  in  a  community  hospital  
hemotherapeutic  agents  were  not  consistently
ocumented  and  hence  not  extracted  in  detail.
dditionally, this  is  a  study  of  a  patient  popula-
ion evaluated  at  a  single  facility  and  based  on  the
valuation  of  available  EMRs,  and  hence  the  pos-
ible use  of  antibiotics  outside  the  system  could
ave been  missed.  The  reason  for  the  prescrip-
ion of  antibiotics  prior  to  the  CDI  and  the  number
f readmissions  after  discharge  were  not  evalu-
ted as  part  of  this  study.  The  primary  aim  of  this
tudy was  to  describe  CDI  in  a  community  hospital
etting and  also  to  conﬁrm  some  of  the  common
bservations in  studies  performed  at  larger  institu-
ions.  The  ﬁndings  of  our  study  also  highlight  the
eed to  revisit  the  practice  of  performing  test-
ng on  multiple  stool  samples,  to  evaluate  the  role
f PPIs  and  encourage  the  use  of  oral  vancomycin
s a  ﬁrst  line  agent  in  patients  at  risk  for  poor
utcomes, especially  the  elderly  with  multiple  co-
orbidities.
onclusions
ur  study  is  consistent  with  the  published  reports
ndicating that  CDI  carries  a  high  mortality  and
orbidity  in  the  elderly  who  often  have  multiple
nderlying co-morbidities.  One  of  the  consistent
redisposing factors  is  the  prior  use  of  antibiotics.
owever, some  patients  developed  CDI  even  in  the
bsence  of  antibiotic  use  in  the  past  six  months,
mplying the  role  of  yet  unidentiﬁed  factors  in  the
athogenesis  of  this  disease.  It  may  be  prudent
o initiate  oral  vancomycin  as  the  ﬁrst-line  ther-
py in  patients  more  than  80  years  of  age  and
atients with  multiple  co-morbidities.  Judicious  use
f antibiotics  and  PPIs  in  the  elderly  combined  with
he early  institution  of  oral  vancomycin  treatment
ay help  reduce  the  mortality  and  morbidity  of  CDI
n our  elderly  population.
unding
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